ROYALTY PHARMA PLC (RPRX) — Hedge Fund Ownership Q4 2025
RPRX
- ROYALTY PHARMA PLC (RPRX) is held by 3 of 82 tracked hedge funds, with Dorsey Asset Management (8%) and Patient Capital Management (5%) holding the largest stakes, indicating limited hedge fund interest relative to peers.
- The biggest increases in RPRX holdings came from Patient Capital Management (+7%) and Torray Investment Partners (+6%), highlighting conviction.
- The biggest decreases in RPRX holdings came from Dorsey Asset Management (-4%), suggesting profit-taking or de-risking.
- Overall, hedge funds increased exposure to ROYALTY PHARMA PLC (RPRX) by +3% vs the prior quarter and +15% vs prior year.
| # | Fund | % of Portfolio † | Shares † | Shares vs Prior Quarter † | Shares vs Prior Year † | Aggregate Value † | Reported Price * | Option |
|---|---|---|---|---|---|---|---|---|
| 1 |
Dorsey Asset Management Pat Dorsey
|
7.59% | 2.3M | -3.87% | — | $87.3M | $38.64 | — |
| 2 |
Patient Capital Management Samantha McLemore
|
4.97% | 3.3M | +6.92% | +15.95% | $128.8M | $38.64 | — |
| 3 |
Torray Investment Partners Robert Torray
|
4.12% | 744K | +5.90% | +8.82% | $28.8M | $38.64 | — |
| 3 | Total | — | 6.3M | +2.70% | +14.58% | $244.9M | — | — |
* Reported price is not an actual purchase or sale price. It is the price as of the last portfolio date.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.